About Evotec
Evotec is a company based in Hamburg (Germany) founded in 1993. Evotec has raised $25 million across 22 funding rounds from investors including Gates Foundation, Mubadala and 3i Group. The company has 4,830 employees as of December 31, 2024. Evotec has completed 11 acquisitions, including Aptuit, CG Germany and CGC Japan. Evotec offers products and services including PanOmics Platform, CRO/CDMO Services, and iPSC Technologies. Evotec operates in a competitive market with competitors including Crown Bioscience, Alloy Therapeutics, Domainex, NIH and Viva Biotech, among others.
- Headquarter Hamburg, Germany
- Employees 4830 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evotec Se
-
Annual Revenue
$827.97 M (USD)1.99as on Dec 31, 2024
-
Net Profit
-$203.71 M (USD)-133.67as on Dec 31, 2024
-
EBITDA
-$72.12 M (USD)-869.17as on Dec 31, 2024
-
Total Equity Funding
$25 M (USD)
in 22 rounds
-
Latest Funding Round
Not available
-
Investors
Gates Foundation
& 14 more
-
Employee Count
4830
as on Dec 31, 2024
-
Investments & Acquisitions
Aptuit
& 10 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Evotec
Evotec is a publicly listed company on the XETR with ticker symbol EVT in Germany, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Evotec
Evotec offers a comprehensive portfolio of products and services, including PanOmics Platform, CRO/CDMO Services, and iPSC Technologies.
AI-powered platform for analyzing disease data and advancing research.
Services for efficient drug development from concept to clinical stages.
Tools for human-relevant disease modeling and therapeutic testing.
People of Evotec
Unlock access to complete
Unlock access to complete
Senior Team
101 people
Software Development Team
53 people
Leadership Team
53 people
Research Team
52 people
Human Resources and Administration
25 people
Finance and Accounting
18 people
Product Management Team
14 people
Principal Team
11 people
Unlock access to complete
Funding Insights of Evotec
Evotec has successfully raised a total of $25M across 22 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evotec
Evotec has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Mubadala and 3i Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Private equity firm focused on mid-market businesses
|
Locked | Locked | Locked | |
|
Private equity investments in healthcare companies are managed.
|
Locked | Locked | Locked |
Investor details for Evotec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evotec
Evotec has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Aptuit, CG Germany and CGC Japan.
Investment portfolio details for Evotec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs
|
Locked | Locked | 2014 | Locked | |
|
Developer and producer of cGMP products for cell-gene therapy
|
Locked | Locked | 2009 | Locked | |
|
Chemical research, production, and development services are provided.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Evotec
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Evotec
Detailed financials for Evotec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evotec Comparisons
Peer comparison for Evotec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evotec
Evotec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Crown Bioscience, Alloy Therapeutics, Domainex, NIH and Viva Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cancer and CVMD drugs are developed using PDX models.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided for therapeutic development.
|
|
| Locked | Locked | Locked |
Drug discovery CRO company for epigenetic research and inflammatory diseases
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery and development research services are provided.
|
Detailed competitors of Evotec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evotec
Complete news archive for Evotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evotec
Evotec was founded in 1993 and raised its 1st funding round 5 years after it was founded.
Evotec is headquartered in Hamburg, Germany. It is registered at Hamburg, Hamburg, Germany.
Evotec is a funded company, having raised a total of $25M across 22 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Evotec is 4,830.
Annual revenue of Evotec is $827.97M as on Dec 31, 2024.
Evotec was founded in 1993 in Hamburg, Germany, as a provider of drug discovery alliance and development services. Operations focus on supporting the biopharma industry through integrated solutions for target identification, screening, and preclinical advancement. Services encompass chemistry, biology, and informatics platforms, with global collaborations extending beyond Europe to facilitate efficient RD pipelines for pharmaceutical partners.
Evotec's top competitors include Crown Bioscience, NIH and Domainex.
Evotec offers PanOmics Platform, CRO/CDMO Services, and iPSC Technologies.
Yes, Evotec is publicly traded on XETR under the ticker symbol EVT.
Evotec has made 11 acquisitions, including Aptuit, CG Germany, and CGC Japan.
Evotec has 15 investors. Key investors include Gates Foundation, Mubadala, 3i Group, CARB-X, and European Union.
The ticker symbol of Evotec is EVT on XETR.